Oncology Drugs Market, by Drug Type (Cytotoxic Drugs (Alkylating Agents, Antimetabolites, and Others), Targeted Drugs (Monoclonal Antibodies, Tyrosine Kinase Inhibitors, and Others), and Hormonal Drugs (Ovarian Function Blockers, Estrogen Production Block

Oncology Drugs Market, by Drug Type (Cytotoxic Drugs (Alkylating Agents, Antimetabolites, and Others), Targeted Drugs (Monoclonal Antibodies, Tyrosine Kinase Inhibitors, and Others), and Hormonal Drugs (Ovarian Function Blockers, Estrogen Production Blockers, and Estrogen’s Effect Blockers (Selective Estrogen Receptor Modulators (SERMs) and Others)), by Cancer Type (Lung Cancer, Breast Cancer, Colorectal Cancer, Prostate Cancer, Blood Cancer, Bladder Cancer, and Others), by Distribution Channel (Hospitals Pharmacies, Retail Pharmacies, and Online Pharmacies), and by Region (North America, Latin America, Europe, Asia Pacific, Middle East, and Africa)- Size, Share, Outlook, and Opportunity Analysis, 2022 - 2030

Group of cells that lose contact inhibition growth mechanism leads to development of tumor, which is potent to grow infinitely at its origin or can invade into blood stream and lead to tumor at different sites. Based on the location ability of tumor cancer, it is classified as benign tumor or malignant tumor, respectively. The global oncology drugs market is segmented by drug type, by cancer type, and by distribution channel. Based on the drug type, market is segmented into cytotoxic drugs, targeted drugs, and hormonal drugs. Targeted drugs specifically target cancerous cells, which helps in reducing the side effects of the drugs. This in turn propels growth of targeted drugs segment.

Market Dynamics

Increasing drug approvals and robust pipeline for novel therapeutic agents are some of the key factors driving the oncology drugs market growth. For instance, in July 2019, In order to advance breakthrough science for the discovery, development, and commercialization of targeted small molecule medicines to treat cancer and other diseases with significant unmet medical needs, Pfizer Inc. announced the successful acquisition of Array BioPharma Inc, an U.S. based clinical stage, pharmaceutical company. Moreover, increasing prevalence of various types of cancer is also fuelling the oncology drugs market growth. For instance, according to a report by American Cancer Society 2021, the estimated number of new cancer cases diagnosed was 1.9 million and 608,570 cancer deaths in the U.S.

However, high cost of cancer drugs and adoption of alternative treatment options such as surgery and radiation therapy are major factors hindering the oncology drugs market growth. For instance, in October 2021, National Cancer Institute released an annual report that stated the national patient economic burden associated with cancer care was more than $21.09 billion, in 2019.Moreover Patients spent a combined $16.22 billion in out-of-pocket costs and $4.87 billion in patient time costs in the U.S.

Key features of the study:

• This report provides in-depth analysis of the global oncology drugs market, market size (US$ Mn), and compound annual growth rate (CAGR (%)) for the forecast period: 2022 – 2030, considering 2021 as the base year
• It elucidates potential revenue opportunity across different segments and explains attractive investment proposition matrix for this market
• This study also provides key insights about market drivers, restraints, opportunities, new product launches or approval, market trends, regional outlook, and competitive strategies adopted by leading players
• It profiles key players in the global oncology drugs market based on the following parameters – company overview, financial performance, product portfolio, geographical presence, distribution strategies, key developments, and strategies
• Key players covered as a part of this study include, Hoffmann-La Roche AG, Novartis International AG, Celgene Corporation, Johnson & Johnson, Bristol-Myers Squibb, Pfizer Inc., Merck & Co., Eli Lilly and Company, AbbVie, Inc., AstraZeneca plc., Bayer AG, and Amgen Inc.
• Insights from this report would allow marketers and management authorities of companies to make informed decision with respect to their future product launches, governmental initiatives, technological up-gradation, market expansion, and marketing tactics
• The global oncology drug market report caters to various stakeholders in this industry, including investors, product manufacturers, distributors, suppliers, research and consulting firms, new entrants, and financial analysts
• Stakeholders would have ease in decision making through various strategy matrices used in analyzing the global disposable gloves market.

Detailed Segmentation:

• Global Oncology Drugs Market, By Drug type:
• Cytotoxic Drugs
• Alkylating Agents
• Antimetabolites
• Others
• Targeted Drugs
• Monoclonal Antibodies
• Tyrosine Kinase Inhibitors
• Others
• Hormonal Drugs
• Ovarian Function Blockers
• Estrogen Production Blockers
• Estrogen’s Effect Blockers
• Selective Estrogen Receptor Modulators (SERMs)
• Others
• Global Oncology Drugs Market, By Cancer type:
• Lung Cancer
• Breast Cancer
• Colorectal Cancer
• Prostate Cancer
• Blood Cancer
• Bladder Cancer
• Others
• Global Oncology Drugs Market, By Distribution Channel:
• Hospital Pharmacies
• Retail Pharmacies
• Online Pharmacies
• Global Oncology Drugs Market, By Region:
• North America
• By Country
• U.S.
• Canada
• Europe
• By Country
• U.K.
• Germany
• Italy
• Spain
• France
• Russia
• Rest of Europe
• Asia Pacific
• By Country
• Australia
• India
• China
• Japan
• ASEAN
• South Korea
• Rest of Asia Pacific
• Latin America
• By Country
• Brazil
• Mexico
• Argentina
• Rest of Latin America
• Middle East
• By Country
• GCC
• Israel
• Rest of Middle East
• Africa
• By Country
• South Africa
• Central Africa
• North Africa
• By Company Profiles
• Hoffmann-La Roche AG.*
• Company Highlights
• Product Portfolio
• Financial Performance
• Recent Highlights
• Market Strategies
• Novartis International AG
• Celgene Corporation
• Johnson & Johnson
• Bristol-Myers Squibb
• Pfizer Inc.
• Merck & Co.
• Eli Lilly and Company
• AbbVie, Inc.
• AstraZeneca plc.
• Bayer AG
• Amgen Inc.

“*” marked represents similar segmentation in other categories in the respective section.